AlphaMark Advisors’s Anavex Life Sciences AVXL Stock Holding History

AlphaMark Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-700	Closed	-$4K	–	538
2017 Q1	$4K	Hold	700	–	–	﹤0.01%	416
2016 Q4	$3K	Hold	700	–	–	﹤0.01%	410
2016 Q3	$3K	Hold	700	–	–	﹤0.01%	306
2016 Q2	$4K	Hold	700	–	–	﹤0.01%	291
2016 Q1	$3K	Hold	700	–	–	﹤0.01%	283
2015 Q4	$4K	Buy	+700	New	+$4.98K	﹤0.01%	258

Other funds holding AVXL

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

AlphaMark Advisors's AVXL Position: Q2 2017 in Review

AlphaMark Advisors sold out of Anavex Life Sciences (AVXL) in Q2 2017, closing a stake of 700 shares — an estimated $4K sold.

AlphaMark Advisors first reported a position in AVXL in Q4 2015 and held it in 6 quarters. The position peaked at $4K in Q1 2017. 61 funds tracked by Wall St. Rank hold AVXL as of Q2 2017.

AlphaMark Advisors reported no remaining Anavex Life Sciences position as of Q2 2017 after selling out during the quarter.
AlphaMark Advisors sold 700 Anavex Life Sciences shares in Q2 2017, an estimated $4K.
AlphaMark Advisors first reported a position in Anavex Life Sciences in Q4 2015 and held it in 6 quarters.
AlphaMark Advisors's Anavex Life Sciences position peaked at $4K in Q1 2017.
61 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2017.

Based on AlphaMark Advisors's 13F filing for Q2 2017, filed 8 Aug 2017.